Pfizer's Stock Price Is Scheduled To Pop

Pfizer's Stock Price Is Scheduled To Pop


On the 3rd of February of 2015, the Food and Drug Administration granted the "accelerated approval to Ibrance to treat advanced breast cancer." The FDA decided to grant Ibrance breakthrough therapy designation, "because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies."



from Biotech News